首页> 外文期刊>Anesthesiology >Evaluation of MP4OX for prevention of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia: a randomized, double-blind, multicenter study.
【24h】

Evaluation of MP4OX for prevention of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia: a randomized, double-blind, multicenter study.

机译:评估MP4OX预防脊麻麻醉下原发性髋关节置换术患者围术期低血压的一项随机,双盲,多中心研究。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: MP4OX (oxygenated polyethylene glycol-modified hemoglobin) is an oxygen therapeutic agent with potential applications in clinical settings where targeted delivery of oxygen to ischemic tissues is required. The primary goal of this study was to investigate MP4OX for preventing hypotensive episodes. An additional goal was to establish the safety profile of MP4OX in a large surgical population. METHODS: Patients (n = 367) from 18 active study sites in six countries, undergoing elective primary hip arthroplasty with spinal anesthesia, were randomized to receive MP4OX or hydroxyethyl starch 130/0.4. Patients received a 250-ml dose at induction of spinal anesthesia and a second 250-ml dose if the protocol-specified trigger (predefined decrease in systolic blood pressure) was reached. The primary end point was the proportion of patients who developed one or more hypotensive episodes. RESULTS: The proportion of patients with one or more hypotensive episodes was significantly lower (P < 0.0001) in the MP4OX group (66.1%) versus controls receiving hydroxyethyl starch 130/0.4 (90.2%). More MP4OX-treated patients experienced adverse events compared with controls (72.7% vs. 61.4%; P = 0.026). Transient elevations in laboratory values (e.g., alanine aminotransferase, aspartate aminotransferase, lipase, and troponin concentrations) occurred more frequently in the MP4OX group. There were no significant differences in the incidence of serious adverse events or in the composite morbidity and ischemia outcome end points, but nausea and hypertension were reported more often in MP4OX-treated patients. CONCLUSION: MP4OX significantly reduced the incidence of hypotensive episodes in patients undergoing hip arthroplasty, but the adverse event profile does not support use in routine low-risk surgical patients for the indication evaluated in this study.
机译:背景:MP4OX(加氧的聚乙二醇修饰的血红蛋白)是一种氧治疗剂,在需要将氧靶向输送至缺血组织的临床环境中具有潜在的应用前景。这项研究的主要目的是研究MP4OX预防高血压发作。另一个目标是建立MP4OX在大量外科手术人群中的安全性。方法:来自6个国家/地区的18个活跃研究地点的患者(n = 367)接受了选择性麻醉和脊柱麻醉的原发性髋关节置换术,随机接受MP4OX或羟乙基淀粉130 / 0.4。患者在诱导脊髓麻醉时接受250毫升剂量,如果达到了协议规定的触发条件(收缩压预先确定的降低),则接受第二次250毫升剂量。主要终点是发生一个或多个降压发作的患者比例。结果:与接受羟乙基淀粉130 / 0.4的对照组(90.2%)相比,MP4OX组(66.1%)发生一次或多次低血压发作的患者比例显着降低(P <0.0001)。与对照组相比,更多接受MP4OX治疗的患者发生了不良事件(72.7%比61.4%; P = 0.026)。 MP4OX组中实验室值(例如丙氨酸转氨酶,天冬氨酸转氨酶,脂肪酶和肌钙蛋白浓度)的短暂升高更为频繁。严重不良事件的发生率或综合发病率和局部缺血结局终点均无显着差异,但用MP4OX治疗的患者恶心和高血压的发生率更高。结论:MP4OX显着降低了接受髋关节置换术患者降压发作的发生率,但不良事件概况不支持常规低危手术患者用于本研究评估的适应症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号